Risk factors
Yarrow Bioscience (YARW) risk factors
Item 1A of every Yarrow Bioscience, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks21 new11 dropped19 reworded
Yarrow is merging with VYNE, resulting in massive dilution where pre-merger VYNE holders retain only 3 percent ownership.
Filed Feb 27, 2026 - FY2024 10-K risk factors66 risks
Clinical-stage biotechnology company dependent on the development of BET inhibitor product candidates repibresib gel and VYN202. Accumulated deficit of $731.2 million with net losses of $39.8 million in 2024. Subject to baby shelf rules limiting capital raising under Form S-3.
Filed Mar 06, 2025